
Claims

1. Use of a compound 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7 naphthyridine of formula (I)



(I)

~~for use~~ in the manufacture of a medicament for the treatment of a hyper-proliferative disease, ~~characterized in that it~~wherein the medicament is to be administered in an amount of from 60 mg to 160 mg per day.

2. The ~~compound for~~ use according to claim 1, ~~characterized in that~~wherein the compound of formula (I) is to be administered in an amount of from 80 mg to 160 mg per day.

3. The ~~compound for~~ use according to claim 1, ~~characterized in that~~wherein the compound of formula (I) is to be administered in an amount of 80 mg per day.

4. The ~~compound for~~ use according to claim 3, ~~characterized in that~~wherein the compound of formula (I) is to be administered in an amount of 40 mg (BID).

5. The ~~compound for~~ use according to claim 4, ~~characterized in that~~wherein the dosing schedule is 3 days on/4 days off.

6. The ~~compound for~~ use according to any one of claims 1 to 5, ~~characterized in that~~wherein the compound of formula (I) is comprised in a pharmaceutical composition ~~according to any of claims 7 to 15~~, the pharmaceutical composition comprising the compound of formula (I) in an amount of 40 mg and at least one pharmaceutically acceptable excipient.

~~7. A pharmaceutical composition comprising the compound of formula (I) in an amount of from 5 mg to 80 mg and at least one pharmaceutically acceptable excipient.~~

~~8. The pharmaceutical composition of claim 7 comprising the compound of formula (I) in an amount of 40 mg.~~

~~9. The pharmaceutical composition of claim 7 comprising the compound of formula (I) in an amount of 20 mg.~~

~~10. The pharmaceutical composition of claim 7 comprising the compound of formula (I) in an amount of 10 mg.~~

~~11. The pharmaceutical composition of any of claims 7 to 10 comprising the compound of formula (I) in a portion of from 3 to 25% by weight of the pharmaceutical composition.~~

~~12. The pharmaceutical composition of any of claims 7 to 11 comprising a glidant.~~

~~13. The pharmaceutical composition of claim 12, characterized in that the glidant is colloidal silicon dioxide.~~

~~14. The pharmaceutical composition of any of claims 7 to 13 comprising spray-dried lactose.~~

~~15. The pharmaceutical composition of any of claims 7 to 14 comprising the compound of formula (I) in a portion of from 16 to 22 %, microcrystalline cellulose in a portion of from 42 to 45 %, lactose monohydrate in a portion of from 31 to 33 %, magnesium stearate in a portion of from 0.5 to 2 %, croscarmellose sodium in a portion of from 2 to 8 % and colloidal silicon dioxide in a portion of from 0.2 to 0.8 % by weight of the pharmaceutical composition.~~

7. The use according to any one of claims 1 to 6, wherein in said use, said hyper-proliferative disease is psoriasis, a keloid, a hyperplasia affecting the skin, benign prostate hyperplasia (BPH), a solid tumour such as a cancer of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid, or a distant metastasis thereof.